Abstracts tagged "Patient reported outcomes"

Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 2029 • ACR Convergence 2023
Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Dina Zucchi³, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare, multisystemic and complex diseases that strongly impact the Quality of Life (QoL) of those affected. Patient Reported Outcomes…
Abstract Number: 2230 • ACR Convergence 2023
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
Laura Coates¹, Robert BM Landewé², Iain McInnes³, Philip J. Mease⁴, Christopher T Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Alice B. Gottlieb¹¹, Richard B. Warren¹², Barbara Ink¹³, Rajan Bajracharya¹³, Jason Coarse¹⁴ and Joseph Merola¹⁵, ¹University of Oxford, Oxford, United Kingdom, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ³University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan, ⁸Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁰Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, ¹²Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹³UCB Pharma, Slough, United Kingdom, ¹⁴UCB Pharma, Morrisville, NC, ¹⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has shown superior efficacy to 16 weeks (wks) vs placebo…
Abstract Number: 026 • 2023 Pediatric Rheumatology Symposium
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Sophie Stefancic, Amanda Robinson, Haley Havrilla, Samantha Branton, Vibha Sood and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gastrointestinal (GI) manifestations in juvenile onset systemic sclerosis (jSSc) reflect adult disease with a range of involvement along the GI tract, including oropharyngeal dysphagia…
Abstract Number: 042 • 2023 Pediatric Rheumatology Symposium
Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Sara Patrizi¹, Susmita Kashikar-Zuck², CARRA Registry Investigators³, Mekibib Altaye⁴ and Jennifer Weiss⁵, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³CARRA, Washington, DC, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, Hackensack, NJ
Background/Purpose: The prevalence, severity and impact of chronic pain in pediatric patients with autoimmune diseases such as childhood onset SLE (cSLE) and juvenile dermatomyositis (JDM)…
Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², CJ Inman¹, Sara Stern¹, Erin Treemarcki², Peter Merkel³ and Karen James¹, ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philidelphia, PA
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
Abstract Number: 058 • 2023 Pediatric Rheumatology Symposium
High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases
Natalie Rosenwasser¹, Tamar Rubinstein², Andrea Knight³, Natoshia Cunningham⁴, Aimee Hersh⁵, Vincent Del Gaizo⁶ and Erin Treemarcki⁵, ¹Seattle Children's Hospital, seattle, WA, ²Children's Hospital at Montefiore, New York, NY, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Michigan State University, Grand Rapids, MI, ⁵University of Utah, Salt Lake City, UT, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ
Background/Purpose: Mental health problems are common in children with pediatric rheumatologic diseases (PRDs) and are associated with worsened quality of life and poorer disease-related outcomes.…
Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Letizia Tarantola³, Roberta Naddei⁴, Alessandro Consolaro², Angela Pistorio⁵ and Angelo Ravelli⁶, ¹IRCCS Istituto Giannina Gaslini, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁴Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, ⁵IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ⁶IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium
Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Claire Yang¹, Natalie Rosenwasser², Xing Wang², Zheng Xu², Joshua Scheck², Ramesh Iyer³ and Yongdong (Dan) Zhao³, ¹University of Washington School of Medicine, Seattle, WA, ²Seattle Children's Hospital, seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Susan Kim¹, Rebecca Olveda² and Jessica Neely², ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Sarvar Nazir¹, Kelly Rouster-Stevens², Julie Fuller³, Hanna Kim⁴, Vy Do⁵, Rita Volochayev⁶, Anna Jansen⁶, Nastaran Bayat⁷, Lisa G Rider⁸ and Adam Schiffenbauer⁶, ¹National Institutes of Health, Charlotte, NC, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³UT Southwestern, Frisco, TX, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁵UT Austin Dell Medical School, Austin, TX, ⁶National Institutes of Health, Bethesda, MD, ⁷Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…
Abstract Number: 0269 • ACR Convergence 2022
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Marijke van den Dikkenberg¹, Martijn Kuijper², Marc Kok¹, Deirisa Lopes Barreto² and Angelique Weel¹, ¹Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam
Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
Abstract Number: 0428 • ACR Convergence 2022
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Devika dua and Tim Blake, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
Background/Purpose: To determine if there is a significant variation in biologic usage in axSpa patients and to identify factors associated with it.Methods: We collected retrospective…
Abstract Number: 0843 • ACR Convergence 2022
Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
Troy B Amen¹, Yi Zhang,¹, John Gibbons¹, Orett Burke¹, Anne Bass², Linda Russell¹, huong do¹, Ying Lai¹, Michael Parks¹, Mark Figgie¹, Bella Mehta³ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Racial and ethnic disparities in total joint arthroplasty utilization have been extensively reported, demonstrating significantly lower rates of utilization among Black and Hispanic patients;…
Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Catherine Bingham¹, Julia Harris², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Tingting Qiu⁷, Jon Burnham⁸, Michelle Batthish⁹, Beth Gottlieb¹⁰, Daniel Lovell⁷, Ronald Laxer¹¹, Tzielan Lee¹², Danielle Bullock¹³, Charles H Spencer¹⁴, Jennifer Weiss¹⁵, Melissa Hazen¹⁶, Edward Oberle¹⁷, Melissa Mannion¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Danielle Fair²¹, Mary Toth²², Kendra Wiegand⁷ and Esi Morgan²³, ¹Penn State Children's Hospital, Hershey, PA, ²Children's Mercy Kansas City, Overland Park, KS, ³Atrium Health Levine Children's, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, ⁶Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁵Hackensack University Medical Center, Hackensack, NJ, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].